3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Cisplatin
47
pembrolizumab
37
Magnetic Resonance Spectroscopy
33
Specimen Handling
27
Radiotherapy, Intensity-Modulated
21
Cetuximab
19
Nivolumab
18
Carboplatin
16
Platinum
15
1,2-diaminocyclohexaneplatinum II citrate
15
Radiotherapy
14
Biopsy
12
Paclitaxel
11
Gemcitabine
10
Docetaxel
10
Surveys and Questionnaires
9
Radiation
9
Immunoglobulin G
7
Disulfides
7
toripalimab
6
cemiplimab
6
Ipilimumab
6
Fluorouracil
6
Bevacizumab
6
dostarlimab
5
atezolizumab
5
Watchful Waiting
5
Taxes
5
Immune Checkpoint Inhibitors
5
Drug Therapy
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Imlunestrant
×
Head & Neck
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled